Digital solutions for the successful development of safe and effective active ingredients
The aim of M2Aind Drugs4Future is the development of a complex ICT-based technology platform for the multimodal analysis of tissues in 2D and 3D for faster, more standardized and more accurate prediction of the safety and effectiveness of pharmaceutical active ingredients in the process of pre-competitive development.
> 90% of all drug candidates in pharmaceutical research that are clinically tested on humans still fail. Obviously, the technologies that evaluate drug candidates preclinically are not predictive enough for the safety and effectiveness in sick people. M2Aind is therefore developing digital technologies that are intended to make a substantial contribution to reducing this “attrition rate”. 11 M2Aind partners are jointly exploring a new molecular high content drug profiling technology platform for faster, more standardized and more accurate prediction of the safety, pharmacokinetic-pharmacodynamics relationship and efficacy of active ingredients in earlier, less capital-intensive steps in pharmaceutical R&D.
Platforms MS imaging, mid-infrared imaging, tissue clarification, 3D cell culture, live cell / 3D fluorescence microscopy from the development phase of the M2Aind innovation partnership are systematically expanded through the integration of further technologies in order to allow an even more comprehensive characterization of tissue treated with active substances: "trapped ion mobility spectrometry" (tims) MS imaging, 4D fluorescence microscopy with 4D perfusion analysis, Raman spectroscopy imaging, laser capture microdissection (3D) bioprinting, microfluidic 3D cell culture and localized chemical derivatization on tissues.
Diverse multimodal data types, namely morphological, molecular, hyperspectral-spectroscopic and functional data and data formats are integrated. The possibilities of data analysis are expanded through the use of machine learning with the main goal of identifying and interpreting complex biomarker signatures. The project is part of the pre-competitive, application-oriented research.
Improving human and animal health is the goal of the research-based pharmaceutical company Boehringer Ingelheim. The focus is on diseases for which there is currently no satisfactory treatment option. The company focuses on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for progressive prevention.